OBJECTIVE: To probe into the clinical efficacy of Shenkang injection combined with alprostadil injection in treatment of chronic renal failure. METHODS: 107 patients with chronic renal failure admitted into Xiangyang No.1 People's Hospital from Jul. 2014 to Jul. 2017 were selected and divided into observation group (54 cases) and control group (53 cases) via random number table. The control group was treated with alprostadil injection, while the observation group was given Shenkang injection combined with alprostadil injection. Differences in renal indices [24 h urine protein quantitation, blood urea nitrogen (BUN), creatinine clearance rate (Ccr) and serum creatinine (SCr) ], blood lipid indices [triacylglycerol (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), apolipoprotein-Al (Apo-Al) and apolipoprotein-B100 (Apo-B100) ], immunological indices [circulating immune complex (CIC), CD3+, CD4+, CD8+ and CD4+/CD8+] and liver function indices [aspartate amino transferase (AST), alanine aminotransferase (ALT) ] between two groups before and after treatment were compared. RESULTS: After treatment, the 24 h urinary protein quantitation, BUN and SCr levels of observation group were significantly lower than those of the control group, while the Ccr level of observation group was significantly higher, with statistically significant differences (P＜0.05); the TG, TC and Apo-B100 levels of observation group were significantly lower than those of the control group, while the HDL-C and Apo-Al levels of observation group were significantly higher, with statistically significant differences (P＜0.05); the CIC and CD8+ levels of observation group were significantly lower than those of the control group, while the CD3+, CD4+ and CD4+/CD8+ levels of observation group were significantly higher, with statistically significant differences (P＜0.05); there were no statistical differences in AST and ALT levels between two groups before and after treatment (P＞0.05). CONCLUSIONS: The combination of Shenkang injection and alprostadil injection in treatment of chronic renal failure can effectively improve patients' renal function, reduce blood lipid level and CIC, with no significant effect on liver function.%目的:探讨肾康注射液联合前列地尔注射液治疗慢性肾衰竭的临床疗效.方法:选取2014年7月至2017年7月襄阳市第一人民医院收治的慢性肾衰竭患者107例作为研究对象,以随机数字表法分为观察组54例和对照组53例.对照组患者给予前列地尔注射液治疗,观察组患者给予肾康注射液联合前列地尔注射液治疗.比较两组患者治疗前后肾功能指标[24 h尿蛋白定量、尿素氮(BUN)、内生肌酐(Ccr)及血清肌酐(SCr)]、血脂指标[三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白-A1(Apo-A1)及载脂蛋白-B100(Apo-B100)]、免疫学指标[循环免疫复合物(CIC)、CD3+、CD4+、CD8+及CD4+/CD8+]和肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)]水平的差异.结果:治疗后,观察组患者24 h尿蛋白定量、BUN及SCr水平明显低于对照组,Ccr水平明显高于对照组,差异均有统计学意义(P＜0.05);观察组患者TG、TC及Apo-B100水平明显低于对照组,HDL-C、Apo-A1水平明显高于对照组,差异均有统计学意义(P＜0.05);观察组患者CIC、CD8+水平明显低于对照组,CD3+、CD4+及CD4+/CD8+水平明显高于对照组,差异均有统计学意义(P＜0.05);治疗前后,两组患者AST、ALT水平的差异均无统计学意义(P＞0.05).结论:肾康注射液联合前列地尔注射液治疗慢性肾衰竭,能够显著改善患者肾功能,降低血脂水平,减少CIC,且对肝功能无明显影响.
展开▼
机译：EficáciadaN-butilescopolamina edipironasódicapomiadasao cetoprofenonoalíviodadorpós-operatóriadepacientes submetidas aduastécnicasdifrentesde laqueadura por laparoscopia Eficacia de la N-butilescopolamina ydipironasódicaasociadasal cetoprofeno en el alivio del dolor pos-operatorio de腹腔镜腹腔镜手术治疗腹腔镜消毒术后患者术后疼痛缓解的N-丁基东莨菪碱和酮二萜钠与酮洛芬联合应用的疗效观察及腹腔镜手术疗效观察
